Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Viridian Therapeutics (VRDN) and Definitive Healthcare Corp (DH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA – Research ...
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Received FDA authorization to initiate ELEVATE-44-102 in the U.S. –– Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. –– ...
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have ...
Bisnow1d
Southern California Student Housing & Higher Education Summit
Join us to hear from industry leaders on the current trends in student housing, higher-ed and university real estate development. Gain insight on which universities and college campuses in Los Angeles ...
BioPharma Dive1d
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
GlobalData on MSN2d
FDA removes clinical hold on Entrada’s Duchenne therapy
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
FierceBiotech3d
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Entrada Shares Climb After FDA Removes Hold on Muscular Dystrophy Treatment
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...
Kapta Space, a Seattle startup working with the Department of Defense, raises $5M
Kapta Space, a radar technology startup based in Seattle, raised $5 million in a seed round led by MetaVC Partners.
Kapta Space launches with $5 million in seed funding to build out its satellite radar technology
Kapta Space plans to innovate space radar technology, enhancing precision and reducing imaging costs with electronically ...